Transgene SA 2021 IR
The report highlights Transgene's progress in 2021, particularly the first positive clinical data from its individualized cancer vaccine TG4050, developed with NEC's artificial intelligence. The company also advanced its oncolytic virus pipeline, with BT-001 entering Phase I/IIa trials and TG6002 demonstrating clinical proof of concept for intravenous administration. Financially, Transgene secured visibility through 2023 following a €34.1 million private placement and the sale of Tasly BioPharmaceuticals shares. On the ESG front, the company established a Corporate Social Responsibility Committee and achieved a score of 92/100 on the Professional Equality Index.
Company: Transgene SA
Sector: Professional & technical services
Country: France
Year: 2021
Type: IR
Pages: 244
Back to company
Transgene SA
Universal Registration Document
The report highlights Transgene's progress in 2021, particularly the first positive clinical data from its individualized cancer vaccine TG4050, developed with NEC's artificial intelligence. The company also advanced its oncolytic virus pipeline, with BT-001 entering Phase I/IIa trials and TG6002 demonstrating clinical proof of concept for intravenous administration. Financially, Transgene secured visibility through 2023 following a €34.1 million private placement and the sale of Tasly BioPharmaceuticals shares. On the ESG front, the company established a Corporate Social Responsibility Committee and achieved a score of 92/100 on the Professional Equality Index.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Published
Apr 6, 2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Women on Board
Women in Management
Employees